Completed PHASE1 INTERVENTIONAL 2-arm NCT01376479

Safety and Immunogenicity Study of an Inactivated Vaccine Against Hand, Foot and Mouth Disease Caused by Enterovirus 71

Phase I, Double Blind, Randomized, Placebo-controlled, Dose Escalation Study to Assess the Safety and Immunogenicity of a Prophylactic Vaccine Against Enterovirus Infection in Healthy Adults

Sponsor: Inviragen Inc.

Conditions Hand, Foot and Mouth Disease

Interventions INV21 High Dose INV21 Low Dose Placebo

Updated 6 times since 2017 Last updated: May 5, 2015 Started: Aug 31, 2011 Primary completion: Nov 30, 2011 Completion: Apr 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Hand, Foot and Mouth Disease, this trial is completed. The trial is conducted by Inviragen Inc. and has accumulated 6 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Aug 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Inviragen Inc.

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Singapore, Singapore